User:Mary Mendoza/Notebook/CHEM572 Exp. Biological Chemistry II/2013/02/19 - Revision history

Mary Mendoza: /* Data */

Mary Mendoza — Wed, 08 May 2013 22:18:21 GMT

Data

←Older revision		Revision as of 22:18, 8 May 2013
Line 9:		Line 9:


-
-	~~==Data==~~
-
-	~~[[Image:NOInhibitorAssay.tiff]]~~

Mary Mendoza: /* Protocol */

Mary Mendoza — Wed, 08 May 2013 22:18:06 GMT

Protocol

←Older revision		Revision as of 22:18, 8 May 2013
Line 8:		Line 8:


-	~~==Protocol==~~
-	* The portion below was taken from the note book of [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/02/19\|Dhea Patel]].
-	* [[Image:Screen_Shot_2013-02-19_at_1.12.45_PM.png]]

-	~~[[Image:Screen_Shot_2013-02-19_at_2.46.05_PM.png]]~~
-
-	*The data obtained from the ADA Assay was not consistent with previous findings, so new Adenosine concentrations were made up according to the following table:
-
-	~~[[Image:Screen_Shot_2013-02-19_at_3.19.14_PM.png]]~~

	==Data==		==Data==

Mary Mendoza: /* ADA Kinetic Assay with Acetylsalicylic Acid inhibitor */

Mary Mendoza — Wed, 08 May 2013 22:17:56 GMT

ADA Kinetic Assay with Acetylsalicylic Acid inhibitor

←Older revision		Revision as of 22:17, 8 May 2013
Line 6:		Line 6:
	\| colspan="2"\|		\| colspan="2"\|
	<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->		<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->
-	~~==ADA Kinetic Assay with Acetylsalicylic Acid inhibitor==~~
-	* The objective for this laboratory period was to run ADA Kinetic assay with the addition of the inhibitor.
-	* Acetylsalicylic acid (C<sub>9</sub>H<sub>8</sub>O<sub>4</sub>, MW 180.16) was obtained from Sigma-Aldrich, Co.
-	* The assay of the acid is ≥ 99.0 %. The solid appeared as a white crystalline form having an absorbance of 230 nm.

-
-	* The first trial conducted did not include the inhibitor for the purpose of obtaining a zero point.
-	* There were observed inconsistencies among the 32, 39.7, 141.8, and 200 μM adenosine concentrations. Thus, new concentrations were calculated for adenosine.

	==Protocol==		==Protocol==

Mary Mendoza: /* Protocol */

Mary Mendoza — Wed, 20 Feb 2013 15:08:56 GMT

Protocol

←Older revision		Revision as of 15:08, 20 February 2013
Line 16:		Line 16:

	==Protocol==		==Protocol==
-	* The portion below was taken from the note book of [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/02/19 Dhea Patel]].	+	* The portion below was taken from the note book of [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/02/19\|Dhea Patel]].
	* [[Image:Screen_Shot_2013-02-19_at_1.12.45_PM.png]]		* [[Image:Screen_Shot_2013-02-19_at_1.12.45_PM.png]]

Mary Mendoza: /* Protocol */

Mary Mendoza — Wed, 20 Feb 2013 15:08:35 GMT

Protocol

←Older revision		Revision as of 15:08, 20 February 2013
Line 16:		Line 16:

	==Protocol==		==Protocol==
-	* The portion below was taken from the note book of [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/02/19	+	* The portion below was taken from the note book of [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/02/19 Dhea Patel]].
-	\|Dhea Patel]].	+
	* [[Image:Screen_Shot_2013-02-19_at_1.12.45_PM.png]]		* [[Image:Screen_Shot_2013-02-19_at_1.12.45_PM.png]]

Mary Mendoza: /* ADA Kinetic Assay with Acetylsalicylic Acid inhibitor */

Mary Mendoza — Wed, 20 Feb 2013 15:07:59 GMT

ADA Kinetic Assay with Acetylsalicylic Acid inhibitor

←Older revision		Revision as of 15:07, 20 February 2013
Line 13:		Line 13:

	* The first trial conducted did not include the inhibitor for the purpose of obtaining a zero point.		* The first trial conducted did not include the inhibitor for the purpose of obtaining a zero point.
-	* There were observed ~~nconsistencies~~ among the 32, 39.7, 141.8, and 200 μM adenosine concentrations. Thus, new concentrations were calculated for adenosine.	+	* There were observed inconsistencies among the 32, 39.7, 141.8, and 200 μM adenosine concentrations. Thus, new concentrations were calculated for adenosine.
		+
		+	==Protocol==
		+	* The portion below was taken from the note book of [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/02/19
		+	\|Dhea Patel]].
		+	* [[Image:Screen_Shot_2013-02-19_at_1.12.45_PM.png]]
		+
		+	[[Image:Screen_Shot_2013-02-19_at_2.46.05_PM.png]]
		+
		+	*The data obtained from the ADA Assay was not consistent with previous findings, so new Adenosine concentrations were made up according to the following table:
		+
		+	[[Image:Screen_Shot_2013-02-19_at_3.19.14_PM.png]]
		+
		+	==Data==
		+
		+	[[Image:NOInhibitorAssay.tiff]]

Mary Mendoza: /* ADA Kinetic Assay with Acetylsalicylic Acid inhibitor */

Mary Mendoza — Tue, 19 Feb 2013 20:02:17 GMT

ADA Kinetic Assay with Acetylsalicylic Acid inhibitor

←Older revision		Revision as of 20:02, 19 February 2013
Line 12:		Line 12:


-	* The first trial conducted did not include the inhibitor.	+	* The first trial conducted did not include the inhibitor for the purpose of obtaining a zero point.
		+	* There were observed nconsistencies among the 32, 39.7, 141.8, and 200 μM adenosine concentrations. Thus, new concentrations were calculated for adenosine.

Mary Mendoza: /* ADA Kinetic Assay with Acetylsalicylic Acid inhibitor */

Mary Mendoza — Tue, 19 Feb 2013 18:29:52 GMT

ADA Kinetic Assay with Acetylsalicylic Acid inhibitor

←Older revision		Revision as of 18:29, 19 February 2013
Line 7:		Line 7:
	<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->		<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->
	==ADA Kinetic Assay with Acetylsalicylic Acid inhibitor==		==ADA Kinetic Assay with Acetylsalicylic Acid inhibitor==
		+	* The objective for this laboratory period was to run ADA Kinetic assay with the addition of the inhibitor.
	* Acetylsalicylic acid (C<sub>9</sub>H<sub>8</sub>O<sub>4</sub>, MW 180.16) was obtained from Sigma-Aldrich, Co.		* Acetylsalicylic acid (C<sub>9</sub>H<sub>8</sub>O<sub>4</sub>, MW 180.16) was obtained from Sigma-Aldrich, Co.
	* The assay of the acid is ≥ 99.0 %. The solid appeared as a white crystalline form having an absorbance of 230 nm.		* The assay of the acid is ≥ 99.0 %. The solid appeared as a white crystalline form having an absorbance of 230 nm.


-	* The first trial conducted did not include ~~any inhibitors~~.	+	* The first trial conducted did not include the inhibitor.

Mary Mendoza: /* Entry title */

Mary Mendoza — Tue, 19 Feb 2013 18:28:52 GMT

Entry title

←Older revision		Revision as of 18:28, 19 February 2013
Line 6:		Line 6:
	\| colspan="2"\|		\| colspan="2"\|
	<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->		<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->
-	==~~Entry title~~==	+	==ADA Kinetic Assay with Acetylsalicylic Acid inhibitor==
-	* ~~Insert content here~~...	+	* Acetylsalicylic acid (C<sub>9</sub>H<sub>8</sub>O<sub>4</sub>, MW 180.16) was obtained from Sigma-Aldrich, Co.
		+	* The assay of the acid is ≥ 99.0 %. The solid appeared as a white crystalline form having an absorbance of 230 nm.
		+
		+
		+	* The first trial conducted did not include any inhibitors.

Mary Mendoza: Autocreate 2013/02/19 Entry for User:Mary_Mendoza/Notebook/CHEM572_Exp._Biological_Chemistry_II

Mary Mendoza — Tue, 19 Feb 2013 18:21:36 GMT

Autocreate 2013/02/19 Entry for User:Mary_Mendoza/Notebook/CHEM572_Exp._Biological_Chemistry_II

New page

{|{{table}} width="800"
|-
|style="background-color: #EEE"|[[Image:owwnotebook_icon.png|128px]]<span style="font-size:22px;"> Project name</span>
|style="background-color: #F2F2F2" align="center"|<html><img src="/images/9/94/Report.png" border="0" /></html> [[{{#sub:{{FULLPAGENAME}}|0|-11}}|Main project page]]<br />{{#if:{{#lnpreventry:{{FULLPAGENAME}}}}|<html><img src="/images/c/c3/Resultset_previous.png" border="0" /></html>[[{{#lnpreventry:{{FULLPAGENAME}}}}{{!}}Previous entry]]<html>      </html>}}{{#if:{{#lnnextentry:{{FULLPAGENAME}}}}|[[{{#lnnextentry:{{FULLPAGENAME}}}}{{!}}Next entry]]<html><img src="/images/5/5c/Resultset_next.png" border="0" /></html>}}
|-
| colspan="2"|

==Entry title==
* Insert content here...


|}

__NOTOC__